These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies. Antonia SJ; Vansteenkiste JF; Moon E Am Soc Clin Oncol Educ Book; 2016; 35():e450-8. PubMed ID: 27249753 [TBL] [Abstract][Full Text] [Related]
3. MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint. Tao Z; Xu S; Ruan H; Wang T; Song W; Qian L; Chen K Cell Physiol Biochem; 2018; 48(2):801-814. PubMed ID: 30032144 [TBL] [Abstract][Full Text] [Related]
4. Cancer Immunotherapy: Diverse Approaches and Obstacles. Sanatkar SA; Heidari A; Rezaei N Curr Pharm Des; 2022; 28(29):2387-2403. PubMed ID: 35909273 [TBL] [Abstract][Full Text] [Related]
5. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141 [TBL] [Abstract][Full Text] [Related]
6. Therapeutic gene modified cell based cancer vaccines. Kozłowska A; Mackiewicz J; Mackiewicz A Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846 [TBL] [Abstract][Full Text] [Related]
7. Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment. Rahimi Kalateh Shah Mohammad G; Ghahremanloo A; Soltani A; Fathi E; Hashemy SI J Cell Physiol; 2020 Jul; 235(7-8):5449-5460. PubMed ID: 31970790 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic strategies for gastric cancer targeting immune cells: Future directions. Zhao Y; Bai Y; Shen M; Li Y Front Immunol; 2022; 13():992762. PubMed ID: 36225938 [TBL] [Abstract][Full Text] [Related]
9. Prostate Cancer Immunotherapy-Finally in From the Cold? Runcie KD; Dallos MC Curr Oncol Rep; 2021 Jun; 23(8):88. PubMed ID: 34125308 [TBL] [Abstract][Full Text] [Related]
10. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386 [TBL] [Abstract][Full Text] [Related]
11. Effective combinatorial immunotherapy for castration-resistant prostate cancer. Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130 [TBL] [Abstract][Full Text] [Related]
12. Sipuleucel-T and immunotherapy in the treatment of prostate cancer. Dawson NA; Roesch EE Expert Opin Biol Ther; 2014 May; 14(5):709-19. PubMed ID: 24620782 [TBL] [Abstract][Full Text] [Related]
13. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations. Wong RL; Yu EY Curr Treat Options Oncol; 2021 Jan; 22(2):13. PubMed ID: 33433743 [TBL] [Abstract][Full Text] [Related]
14. Prostate cancer immunotherapy: the path forward. Madan RA; Gulley JL Curr Opin Support Palliat Care; 2017 Sep; 11(3):225-230. PubMed ID: 28644303 [TBL] [Abstract][Full Text] [Related]
15. Targeting the spectrum of immune checkpoints in prostate cancer. Sena LA; Denmeade SR; Antonarakis ES Expert Rev Clin Pharmacol; 2021 Oct; 14(10):1253-1266. PubMed ID: 34263692 [No Abstract] [Full Text] [Related]
16. Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors. Barroso-Sousa R; Ott PA Curr Oncol Rep; 2018 Nov; 21(1):1. PubMed ID: 30498900 [TBL] [Abstract][Full Text] [Related]
18. PD-L1 Inhibitors for the Treatment of Prostate Cancer. Santoni M; Massari F; Cheng L; Cimadamore A; Scarpelli M; Montironi R; Lopez-Beltran A Curr Drug Targets; 2020; 21(15):1558-1565. PubMed ID: 32516098 [TBL] [Abstract][Full Text] [Related]
19. Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer. Sinha M; Zhang L; Subudhi S; Chen B; Marquez J; Liu EV; Allaire K; Cheung A; Ng S; Nguyen C; Friedlander TW; Aggarwal R; Spitzer M; Allison JP; Small EJ; Sharma P; Fong L J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33986125 [TBL] [Abstract][Full Text] [Related]
20. How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Stultz J; Fong L Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):697-717. PubMed ID: 33820953 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]